A review of agitation in mental illness: Treatment guidelines and current therapies

Journal of Clinical Psychiatry

Volumn 67, Issue SUPPL. 10, 2006, Pages 13-21

  Marder, Stephen R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; CHLORDIAZEPOXIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DIAZEPAM; DIPHENHYDRAMINE; FLUNITRAZEPAM; HALOPERIDOL; LORAZEPAM; MIDAZOLAM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIHEXYPHENIDYL; ZIPRASIDONE;

AGITATION; AKATHISIA; BEHAVIOR DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; INFORMED CONSENT; MEDICAL DECISION MAKING; MENTAL DISEASE; MENTAL PATIENT; NEUROLEPTIC MALIGNANT SYNDROME; PATIENT CARE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SCORING SYSTEM; SLEEP; TABLET FORMULATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

AGGRESSION; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HUMANS; MENTAL DISORDERS; PRACTICE GUIDELINES; PSYCHOMOTOR AGITATION; RESTRAINT, PHYSICAL; SOCIAL ISOLATION; VIOLENCE;

EID: 33748945158     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Department of Health and Human Services, US Food and Drug Administration. Center for Drug Evaluation and Research. Transcript of the Psychopharmacological Drugs Advisory Committee Meeting on NDA 21-253; Feb 14, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3685tl. txt. Accessibility verified June 23, 2006
2. Keck PE, McElroy SL, Arnold LM. Advances in the pathophysiology and treatment of psychiatric disorders: implications for internal medicine. Med Clin North Am 2001;85:645-661
3. Marco CA, Vaughan J. Emergency management of agitation in schizophrenia. Am J Emerg Med 2005;23:767-776
4. Teri L, Borson S, Kiyak HA, et al. Behavioral disturbance, cognitive dysfunction, and functional skill: prevalence and relationship in Alzheimer's disease. J Am Geriatr Soc 1989;37:109-116
5. Bartels SJ, Horn SD, Smout RJ, et al. Agitation and depression in frail nursing home elderly patients with dementia. Am J Geriatr Psychiatry 2003;11:231-238
6. Battaglia J. Pharmacologic management of acute agitation. Drugs 2005;65:1207-1222
7. Petit J. Management of the acutely violent patient. Psychiatr Clin North Am 2005;28:701-711
8. Buckley PF, Noffsinger SG, Smith DA, et al. Treatment of the psychotic patient who is violent. Psychiatr Clin North Am 2003;26:231-272
9. Mendelowitz AJ. Assessment and treatment of acute psychotic agitation in the emergency room setting. Essent Psychopharmacol 2002;5:31-43
10. Lindenmayer JP. The pathophysiology of agitation. J Clin Psychiatry 2000;61(suppl 14):5-10
11. Allen MH. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry 2000;61(suppl 14):11-20
12. Battaglia J, Lindborg SR, Alaka K, et al. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 2003;21:192-198
13. American Association for Geriatric Psychiatry (AAGP). AAGP Position Statement on the FDA Proposal for the March 9, 2000 Meeting. (FDA docket number 00N-0088). Available at: http://www.fda.gov/ohrms/dockets/dockets/00n0088/ c000004.pdf. Accessed July 7, 2005
14. American Hospital Formulary Service. 28:16.08 Antipsychotics. In: AHFS Drug Information. Bethesda, Md: American Society of Health-System Pharmacists; 2004:2271-2331
15. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes and sudden death. Am J Psychiatry 2001;158:1774-1782
16. Lazurus A, Dubin WR, Jaffe RL. Rapid tranquilization with neuroleptic drugs; neurologic concerns. Clin Neuropharmacol 1989;12:303-311
17. Risperdal [package insert]. Titusville, NJ: Janssen Pharmaceutica; 2005
18. Zyprexa [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2005
19. Geodon [package insert]. New York, NY: Pfizer; May 2005
20. Ability [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; December 2005
21. Seroquel [package insert]. Wilmington, Del: AstraZeneca Pharmaceuticals LP; 2005
22. Citrome L. Atypical antipsychotics for acute agitation: new intramuscular options offer advantages. Postgrad Med 2002;112:85-88, 94-96
23. Awad AG, Vorunganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004;18:877-893
24. Preval H, Klotz SG, Southard R, et al. Rapid-acting IM ziprasidone in the psychiatric emergency service: a naturalistic study. Gen Hosp Psychiatry 2005;27:140-144
25. Lukens TW, Wolf SJ, Edlow JA, et al. Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department. From the American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in the Emergency Department. Ann Emerg Med 2006;47:79-99
26. Brook S. Intramuscular ziprasidone: moving beyond the conventional in treatment of acute agitation in schizophrenia. J Clin Psychiatry 2003;64(suppl 19):13-18
27. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular IM ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001;155:128-134
28. Battaglia J. Intramuscular olanzapine: treating acute agitation in psychosis and bipolar mania. Curr Psychiatry 2004;3:76-78
29. Brier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441-448
30. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149-1151
31. Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21:389-397
32. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-69
33. Cohen S, Khan A. Adjunctive benzodiazepines in acute schizophrenia. Neuropsychobiology 1987;18:9-12
34. Foster S, Kessel J, Berman ME, et al. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 1997;12:175-179
35. Lenox RH, Newhouse PA, Creelman WL, et al. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double blind study. J Clin Psychiatry 1992;53:47-52
36. Salzman C, Solomon D, Miyawaki E, et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 1991;52:177-180
37. Greenblatt DJ, Miller LG, Shader RI. Clonazepam pharmacokinetics, brain uptake and receptor interactions. J Clin Psychiatry 1987;48 (suppl 10):4-11
38. Medoza R, Djenderedijan AH, Adams J, et al. Midazolam in acute psychotic patients with hyperarousal. J Clin Psychiatry 1987;48:291-292
39. Gaudreault P, Guay J, Thivierge RL, et al. Benzodiazepine poisoning: clinical and pharmacologic considerations and treatment. Drug Saf 1991;6:247-265
40. Shorr RI, Robin DW. Rational use of benzodiazepines in the elderly. Drugs Aging 1994;4:9-20
41. Hughes DH, Kleespies PM. Treating aggression in the psychiatric emergency service. J Clin Psychiatry 2003;64(suppl 4):10-15
42. Young RC. Evidence-based pharmacologic treatment of geriatric bipolar disorder. Psychiatr Clin North Am 2005;28:837-869
43. Allen MH, Currier GW. Use of restraints and pharmacotherapy in academic psychiatric emergency services. Gen Hosp Psychiatry 2004;26:42-49
44. Alexopoulos GS, Streim JE, Carpenter D. Expert Consensus Guidelines for Using Antipsychotic Agents in Older Patients [commentary]. J Clin Psychiatry 2004;65(suppl 2):100-102
45. Royal College of General Practitioners. Guidance for the management of behavioural and psychiatric symptoms in dementia and the treatment of psychosis in people with history of stroke/TIA. Royal College of General Practitioners; March 5, 2004
46. Allen MH, Currier GW, Hughes DH, et al. Treatment of behavioral emergencies: a summary of the expert consensus guidelines. J Psychiatr Pract 2003;9:16-38
47. Hansberry MR, Chen E, Gorbien MJ. Dementia and elder abuse. Clin Geriatr Med 2005;21:315-332
48. Mintzer J, DeVane L, Wets B, et al. Aripiprazole effects on highly agitated patients with Alzheimer's disease and associated psychosis. Presented at the 44th Annual Meeting of the American College of Neuropsychopharmacology; December 11-15, 2005; Walkoloa, Hawaii. Poster 150
49. US Food and Drug Administration (FDA). FDA Talk Paper: FDA Issues Public Health Advisory for Antipsychotic Drugs Used for Treatment of Behavioral Disorders in Elderly Patients. Available at: http://www.fda.gov/bbs/topics/ ANSWERS/2005/ANS01350.html.Access verified April 19, 2006
50. Zun LS, Downey L. The use of seclusion in emergency medicine. Gen Hosp Psychiatry 2005;27:365-371